| Kindrela Culver, | |
|
1700 Cedar Springs Rd Apt 1614, Dallas, TX 75202-1217 | |
| (972) 514-2840 | |
| Not Available |
| Full Name | Kindrela Culver |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 1700 Cedar Springs Rd Apt 1614, Dallas, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023756178 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | P325077 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kindrela Culver, 1700 Cedar Springs Rd Apt 1614, Dallas, TX 75202-1217 Ph: (972) 514-2840 | Kindrela Culver, 1700 Cedar Springs Rd Apt 1614, Dallas, TX 75202-1217 Ph: (972) 514-2840 |
News Archive
The Department of Health and Human Services said on Thursday that it would provide 25 of the 50 states with funding to test new ways to lower costs and improve care within the national Medicaid program for the poor.
Administering heart resuscitation drugs to patients whose cardiac arrest is witnessed at the time of the attack can improve survival, but needs to be done through an IV line rather than directly into bone marrow as is more commonly done by paramedics, a new study involving UT Southwestern Medical Center emergency physicians and Dallas-Fort Worth Emergency Medical Services agencies reveals.
Anacor Pharmaceuticals, Inc. today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in the offering will be offered by Anacor.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 4 days ago
Greg Nnaemeka Okeh, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 11110 Woodmeadow Pkwy Apt 312, Dallas, TX 75228 Phone: 708-257-5076 | |
Fathimat B Oladiti, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 13601 Preston Rd Ste 210w, Dallas, TX 75240 Phone: 972-702-0300 | |
Maggie Abwo Kasto I, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 6864 Larmanda St Apt 276, Dallas, TX 75231 Phone: 214-962-8023 | |
Dawn Russell, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 13737 Noel Rd Ste 1400, Dallas, TX 75240 Phone: 214-754-8700 Fax: 877-614-6192 | |
Jecinta Wanjiku Kamau, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 9655 Chimney Hill Ln Apt 2075, Dallas, TX 75243 Phone: 214-470-1373 | |
Sigrid Kagoiya, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 13601 Preston Rd Ste 210w, Dallas, TX 75240 Phone: 972-702-0300 |